In January 2028, I will ask a leading AI model whether AI has improved drug discovery (made it significantly faster or cheaper or other). Martin Shkreli claims “AI does not help drug discovery”.
Resolution criteria
This market resolves to YES if, in January 2028, a query to a leading AI model yields a response concluding that AI development has improved drug discovery (for example, by making it faster, cheaper, or more effective). Otherwise, this market resolves to NO.
Resolution will be determined by the market creator based on the output of a state-of-the-art flagship AI model queried in January 2028. If the AI model's response is ambiguous or inconclusive, the market creator will determine resolution based on the plain-language interpretation of the output.
Background
Former pharmaceutical executive Martin Shkreli has publicly argued that AI does not meaningfully assist drug discovery, contending that machine learning does not solve the primary biological, safety, and clinical bottlenecks inherent to drug development. In contrast, proponents of AI in biotechnology highlight tools like AlphaFold and machine learning platforms used to accelerate target identification, protein structure prediction, and candidate molecule generation. This market evaluates whether AI models in early 2028 assess that AI has demonstrably improved the drug discovery process.
This description was generated by AI. Review and verify everything here yourself. You can edit, replace, or delete any part of this description, including the resolution criteria. You do not need to trust the AI output.
1,000